The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Precision BioSciences Inc. (DTIL) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.04, or -2.94%, to $1.32. Volume reached 12,355 shares, with price reaching a high of $1.32 and a low of $1.26. Earlier, Yahoo Finance discussed this stock as it revealed Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit.
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $1.27 and fluctuated between $1.3600 as its day high and $1.2300 as its day low. The current market capitalization of Precision BioSciences Inc. is $152.73M. A total of 1.58 million shares were traded on the day, compared to an average of 3.18M shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, DTIL has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 12 BUYs and 2 SELLs from insiders. Insiders purchased 183,292 shares during that period but sold 28,682.
In the most recent transaction, Kelly John Alexander bought 33,784 shares of DTIL for 1.50 per share on Jun 22. After the transaction, the Chief Financial Officer now owns 117,701 company shares. In a previous transaction on Jun 08, JANTZ DEREK sold 18,849 shares at 2.06 per share. DTIL shares that Chief Scientific Officer owns now total 4,055,174.
Among the insiders who sold shares, Scimeca Dario disposed of 9,833 shares on Jun 08 at a per-share price of $2.06. This resulted in the General Counsel and Secretary holding 32,514 shares of DTIL after the transaction. In another insider transaction, List Alan sold 7,775 shares at $2.10 per share on Apr 27. Company shares held by the Chief Medical Officer now total 18,260.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for DTIL in the last 3 months, the mean price target is $8.22 with high estimates of $20.00 and low estimates of $2.00. In terms of 52-week highs and lows, DTIL has a high of $13.49 and a low of $1.11.
As of this writing, DTIL has an earnings estimate of $-0.35 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of $-0.26 per share and a lower estimate of $-0.48. The company reported an EPS of $-0.44 in the last quarter, which was -2.33% lower than expectations of $-0.43.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 10 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DTIL is Hold with a score of 4.33. A total of 6 analysts rated the stock as Buy while 1 rated it as Overweight while 3 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.